UK Markets close in 3 hrs 18 mins
  • FTSE 100

    7,442.71
    +139.97 (+1.92%)
     
  • FTSE 250

    20,026.92
    +337.90 (+1.72%)
     
  • AIM

    961.64
    +14.47 (+1.53%)
     
  • GBP/EUR

    1.1792
    +0.0010 (+0.09%)
     
  • GBP/USD

    1.2474
    -0.0000 (-0.0037%)
     
  • BTC-GBP

    24,336.76
    +645.10 (+2.72%)
     
  • CMC Crypto 200

    678.08
    +25.85 (+3.96%)
     
  • S&P 500

    3,900.79
    -22.89 (-0.58%)
     
  • DOW

    31,253.13
    -236.94 (-0.75%)
     
  • CRUDE OIL

    112.79
    +0.58 (+0.52%)
     
  • GOLD FUTURES

    1,840.30
    -0.90 (-0.05%)
     
  • NIKKEI 225

    26,739.03
    +336.19 (+1.27%)
     
  • HANG SENG

    20,717.24
    +596.56 (+2.96%)
     
  • DAX

    14,152.10
    +269.80 (+1.94%)
     
  • CAC 40

    6,374.03
    +101.32 (+1.62%)
     

LAVA Therapeutics to Participate at the UBS Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Lava Therapeutics N.V.
Lava Therapeutics N.V.

UTRECHT, The Netherlands and PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a fireside chat at the UBS Global Healthcare Conference 2022 being held in New York, NY.

Presentation Details
Format: Fireside chat
Date: Monday, May 23, 2022
Time: 4:15-4:45p.m. ET.

A live webcast of the fireside chat and a replay of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at: https://ir.lavatherapeutics.com/news-events/events.

About LAVA Therapeutics
LAVA Therapeutics N.V. is an immuno-oncology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid and hematological malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor associated antigens. LAVA-051, the Company’s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study (NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling. For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.

CONTACTS
Edward Smith
Chief Financial Officer
ir@lavatherapeutics.com

Argot Partners (IR/Media)
212-600-1902
lava@argotpartners.com



Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting